Publications by authors named "Thomas Donner"

Claim this Profile
I
Invariant VD and DJ Motifs Define a Novel Class of Human Antibodies and TCRs Prototyped by antigen receptors of Dual-Expresser Lymphocytes.
Neha Majety, Rizwan Ahmed, Rafid Al-Hallaf, Prajita Paul, Adebola Giwa, Thomas Donner

Immunol Invest· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes.
Colleen Gavigan, Thomas Donner

J Diabetes Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature.
Hasan Husni, Sara A Khan, Buraq Alghaieb, Mohammed S Abusamaan, Thomas W Donner

Clin Case Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device.
A M James Shapiro, David Thompson, Thomas W Donner, Melena D Bellin, Willa Hsueh

Cell Rep Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reply to "TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes".
Rizwan Ahmed, Zahra Omidian, Adebola Giwa, Thomas Donner, Chunfa Jie

Cell· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment.
Adebola Matthew Giwa, Rizwan Ahmed, Zahra Omidian, Neha Majety, Kagan Ege Karakus, Thomas Donner

World J Diabetes· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-17 and limits of success.
Zahra Omidian, Rizwan Ahmed, Adebola Giwa, Thomas Donner, Abdel Rahim A Hamad

Cell Immunol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen.
Rizwan Ahmed, Zahra Omidian, Adebola Giwa, Benjamin Cornwell, Neha Majety, Thomas Donner

Cell· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technology.
Rizwan Ahmed, Zahra Omidian, Thomas Donner, Abdel Rahiam A Hamad

Discov Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Ying and Yang Members of the Tumor Necrosis Factor Superfamily: Friends or Foes in Immune-Mediated Diseases and Cancer.
Adebola Giwa, Rizwan Ahmed, Thomas Donner, Hideo Yagita, Abdel Rahim A Hamad

Front Immunol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expansion of FasL-Expressing CD5 B Cells in Type 1 Diabetes Patients.
Ankit Saxena, Hideo Yagita, Thomas W Donner, Abdel Rahim A Hamad

Front Immunol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B cell-targeted immunotherapy for type 1 diabetes: What can make it work?
Abdel Rahim A Hamad, Rizwan Ahmed, Thomas Donner, Georgia Fousteri

Discov Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
Joshua J Joseph, Thomas W Donner

Vasc Health Risk Manag· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.
Ankit Saxena, Sam Khosraviani, Sanjeev Noel, Divya Mohan, Thomas Donner

Cytokine· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi

Diabetes Care· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
Richard G Bach, Maria Mori Brooks, Manuel Lombardero, Saul Genuth, Thomas W Donner

Circulation· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-priority research needs for insulin delivery and glucose monitoring methods.
Hsin-Chieh Yeh, Brandyn D Lau, Sherita H Golden, Thomas Donner, Todd T Brown

J Diabetes Sci Technol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Richard G Bach, Maria Mori Brooks, Manuel Lombardero, Saul Genuth, Thomas W Donner

Circulation· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data.
Parag H Joshi, Rita R Kalyani, Roger S Blumenthal, Thomas W Donner

Am J Cardiol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes.
Abdel Rahim A R Hamad, Kristin Arcara, Sophia Uddin, Thomas Donner

Front Immunol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on insulin therapy for type 2 diabetes.
Thomas Donner, Miguel Muñoz

J Clin Endocrinol Metab· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive training of subjects with chronic hemiparesis on a motorized cycle combined with functional electrical stimulation (FES): a feasibility and safety study.
Gad Alon, Vincent M Conroy, Thomas W Donner

Physiother Res Int· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary supplementation with d-tagatose in subjects with type 2 diabetes leads to weight loss and raises high-density lipoprotein cholesterol.
Thomas W Donner, Laurence S Magder, Kiarash Zarbalian

Nutr Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes.
Fadia T Shaya, Xia Yan, Pei-Jung Lin, Linda Simoni-Wastila, Morgan Bron, Thomas W Donner

J Clin Hypertens (Greenwich)· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis